Citalopram in the treatment of dysthymic disorder

International Clinical Psychopharmacology

Volumn 19, Issue 3, 2004, Pages 143-148

  Hellerstein, David J ^a,b   Batchelder, Sarai ^b   Miozzo, Ruben ^c   Kreditor, David ^d   Hyler, Steven ^b   Gangure, Dinu ^b   Clark, Joy ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Chronic depression; Citalopram; Dysthymic disorder; Psychopharmacology; Selective serotonin reuptake inhibitor; Treatment response

Indexed keywords

CITALOPRAM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSTHYMIA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAMILTON SCALE; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; IRRITABILITY; MALE; MICTURITION DISORDER; PRIORITY JOURNAL; SELF REPORT; SEXUAL DYSFUNCTION; SWEAT; SYMPTOMATOLOGY; TEMPERAMENT; TREATMENT OUTCOME; VISUAL IMPAIRMENT; XEROSTOMIA; YAWNING;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTHYMIC DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 2342520666     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200405000-00004     Document Type: Article

References (35)

1. Agosti V, McGrath PJ (2002). Comparison of the effects of fluoxetine, imipramine and placebo on personality in atypical depression. J Affect Dis 71:113-120.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
3. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK (1961). An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
4. Brooks J, Baker GA, Aldenkamp AP (2001). The A-B neuropsychological assessment schedule (ABNAS): the further refinement of a patient-based scale of patient-perceived cognitive functioning. Epilepsy Res 43:227-237.
5. Chien AJ, Dunner DL (1996). The tridimensional personality questionnaire in depression: state versus trait issues. J Psychiatry Res 30:21-27.
6. Cloninger CR, Przybeck TR, Svrakic DM (1991). The Tridimensional Personality Questionnaire: U.S. normative data. Psychol Rep 69:1047-1057.
7. Cloninger CR, Svrakic DM, Przybeck TR (1993). A psychobiological model of temperament and character. Arch Gen Psychiatry 50:975-990.
8. Davidson JRT, Connor KM (1998). Citalopram: a therapeutic overview. J Clin Psychiatry 59 (suppl 4):25-31.
9. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L (1974). The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behav Sci 19:1-15.
10. Dewan MJ, Anand VS (1999). Evaluating the tolerability of the newer antidepressants. J Nerv Ment Dis 187:96-101.
11. Dunner DL, Hendrickson HE, Bea C, Budech CB (1997). Venlafaxine in dysthymic disorder. J Clin Psychiatry 58:528-531.
12. Dunner DL, Hendricksen HE, Bea C, Budech CB, Friedman SD (2002). Dysthymic disorder: treatment with citalopram. Depress Anxiety 15:18-22.
13. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse and recurrence. Arch Gen Psychiatry 48:851-855.
14. Friedman RA (1993). Social impairment in dysthymia. Psychiatr Annals 23:623-637.
15. Guy W (editor) (1976). ECDEU Assessment Manual for Psychopharmacology. Publication no. ADM 76-338. Rockville, MD: National Institute of Mental Health.
16. Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Kasch K, et al. (1993). A randomized double-blind study of fluoxetine versus placebo in treatment of dysthymia. Am J Psychiatry 150:1169-1175.
17. Hellerstein DJ, Batchelder ST, Little SAS, Fedak M, Kreditor D, Rosenthal J (1999). Venlafaxine in the treatment of dysthymia: an open-label study. J Clin Psychiatry 60:845-849.
18. Hellerstein DJ, Kocsis JH, Chapman D, Stewart JW, Harrison W (2000). Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: effects on personality. Am J Psychiatry 157:1436-1444.
19. Hellerstein DJ (2001a). Dysthymic disorder: integrating research findings into clinical treatment. J Psychiatr Pract 7:298-309.
20. Hellerstein DJ, Batchelder ST, Kreditor D, Fedak M (2001b). Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study. J Clin Psychopharmacol 21:325-329.
21. Hellerstein DJ, Batchelder ST, Lee A, Borisovskaya M (2002). Rating dysthymia: an assessment of the construct and content validity of the Cornell Dysthymia Rating Scale. J Affect Dis 71:85-96.
22. Howland RH (1991). Pharmacotherapy of dysthymia: a review. J Clin Psychopharmacol 11:83-92.
23. Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, et al. (1997). Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry 154:390-395.
24. Keller MB, Hanks DL (1995). Course and natural history of chronic depression. In: Kocsis JH, Klein DN (editor): Diagnosis and Treatment of Chronic Depression. New York: Guilford Press; pp. 58-72.
25. Keller MB, Klein DN, Hirshfeld RMA, Kocsis JH, McCullough JP, Miller I, et al. (1995). Results of the DSM-IV Mood Disorders Field Trial. Am J Psychiatry 152:843-849.
26. Lapierre YD (1994). Pharmacological therapy of dysthymia. Acta Psychiatr Scand 89:42-48.
27. Marin DB, Kocsis JH, Frances AJ, Parides MS (1994). Desipramine for the treatment of 'pure' dysthymia versus 'double' depression. Am J Psychiatry 151:1079-1080.
28. Mason BJ, Kocsis JH, Leon AC, Thompson S, Frances AJ, Morgan RO, Parides MK (1993). Measurement of severity and treatment response in dysthymia. Psychiatr Annals 23:625-631.
29. Moberg PJ, Lazarus LW, Mesholam RI, Bilker W, Chuy IL, Neyman I, Markvart V (2001). Comparison of the standard and structured interview guide for the Hamilton Depression Rating Scale in depressed geriatric inpatients. Am J Geriatr Psychiatry 9:35-40.
30. Ravindran AV, Charbonneau Y, Zaharia MD, Al-Zaid K, Wiens A, Anisman H (1998). Efficacy and tolerability of venlafaxine in the treatment of primary dysthymia. J Psychiatry Neurosci 23:288-292.
31. Settle EC (1998). Citalopram: Side effect profile. J Clin Psychiatry 59 (suppl 4):32-36.
32. Spitzer RL, Williams JBW, Gibbon M (1988). Structured Clinical Interview for DSM-III-R, Patient Version (SCID-P). New York: New York State Psychiatric Institute, Biometrics Research.
33. Thase ME, Fava M, Halbreich VJ, Kocsis JH, Koran L, Davidson J et al. (1996). A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 53:777-784.
34. Weissman MM (1999). Social Adjustment Scale-Self Report (SAS-SR). North Tonawanda, New York: Multi-Health Systems, Inc.
35. Wu AW, Revicki DA, Jacobson D, Malitz FE (1997). Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 6:481-493.